Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

ted at all three doses in this study is very encouraging for the prospects of ANA598 when used in combination with other HCV agents. With the successful conclusion of this study in patients and the 14-day study in healthy volunteers, the positive 13-week animal toxicology results and ongoing manufacturing activities, the ANA598 program continues on track to be ready for Phase II in mid-2009."

The Phase Ib study was a randomized, double-blind, placebo-controlled, multiple ascending dose trial conducted to evaluate the safety, tolerability and antiviral activity of orally administered ANA598 in treatment-naive patients with chronic HCV genotype 1 infection. Patients were treated with ANA598 capsules (or matching placebo) at doses of 200 mg, 400 mg or 800 mg bid for three days. 35 patients participated in the study, with 11 receiving 200 mg bid, eight receiving 400 mg bid, eight receiving 800 mg bid and eight receiving placebo (with none of the patients receiving placebo showing an end of treatment response greater than 0.2 log10 reduction in viral load). Viral load at Day 4 (12 hours after the last dose) was compared to baseline HCV RNA levels.

"We're very pleased with the antiviral activity and safety of ANA598 in this study," commented James Freddo, M.D., Senior Vice President, Drug Development and Chief Medical Officer. "We believe the data continue to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV, and we look forward to investigating ANA598 in longer-term studies in combination with current standard of care."

ANA598 Program Update

Anadys continues to make progress on all aspects of the ANA598 program, including toxicology, manufacturing and a recently completed 14-day clinical study in healthy volunteers. The Company reiterates its expectation for the program to be ready mid-year for the first Phase II study of ANA598 in combination wi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today ... William Resnick have been elected to Medimetriks, ... Mr. Lary, who will serve on Medimetriks, ... investment experience to the Company.  Mr. Lary is ... LLC, a leading institutional investment firm.  Mr. Lary ...
(Date:9/23/2014)... YORK , September 23, 2014 ... pioneer in computer-aided dysmorphology analysis will exhibit at the ... Diego, CA. FDNA will present the latest ... and reference solution, using facial analysis technology. Face2Gene facilitates ... of human malformations from facial photos. The ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4
... Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ ... second U.S. center, and first in the Northeast, ... part of the DuraHeart Bridge-To-Transplant U.S. pivotal trial, ... in up to 40 centers nationwide. The ...
... The American Medical Association (AMA) Foundation announced today the 28 recipients of ... provides $2,500 grants to medical students, physician residents and fellows to conduct ... are conducting research in the following four categories: , , ... , HIV/AIDS , ...
Cached Medicine Technology:Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 2Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 3AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:9/23/2014)... 23, 2014 Dr. Connie Casad has announced ... to new office space at 12200 Park Central Drive, Suite ... office will be Park Cities Aesthetics, Optimal Health and Wellness, ... announcing her move, Dr. Casad said, “The patients’ comfort and ... select, we want them to always feel like their needs ...
(Date:9/23/2014)... rapidly developing, bringing with its advances promises of ... and treatment interventions. Genetic tests are already ... and hepatitis c virus (HPC), and emerging research ... screen for an individual,s susceptibility to addiction to ... , While there appear to be many benefits ...
(Date:9/23/2014)... -- Few children who take medication for attention-deficit/hyperactivity ... rates vary six-fold across counties in the United ... can manage symptoms for many children with ADHD, ... behavioral therapy (psychotherapy), the Rand Corp. researchers noted. ... 1,500 counties across the United States that included ...
(Date:9/23/2014)... Ill. (September 23, 2014) Both patients and ... screening computed tomography (CT) colonography greatly outweighs the ... tests precipitated by false-positive diagnoses, according to a ... the journal Radiology . , Diagnostic tests ... specific organ. However, when screening for colorectal cancer ...
(Date:9/23/2014)... SOURCE: Solutions from Our Country’s ... made to Rimidi Diabetes and TruClinic ... business solutions to challenges faced by patients and healthcare ... between The Hitachi Foundation, Village Capital, ... with the investment capital, mentoring, and support needed to ...
Breaking Medicine News(10 mins):Health News:Dr. Connie Casad Moving to New Office Location 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... ... Shows Pointing to Words During Story Time Enhances Children,s Literacy Development , ... Rockville, MD (Vocus) May 4, 2010 -- While ... study suggests that by pointing to the words being read and talking about print, children,s ...
... , ... Show How Women Health Workers Can Save Children,s Lives, Fill Key Health Care Gaps Around the ... Westport, Conn. (Vocus) -- To ... child deaths, countries must invest in women who are front-line health care workers, Save the Children ...
... be an effective preventive measure, researchers say , TUESDAY, May ... be one way to slow the HIV/AIDS epidemic, according to ... greater risk for HIV infection than those not infected with ... 18 to 24, who were uncircumcised, did not have HIV ...
... 4, 2010) Rates of colorectal cancer screening vary ... to data being presented at Digestive Disease Week (DDW) ... as well as utilization rates of virtual and optical ... DDW is the largest international gathering of physicians ...
... ... of the best hospitals and clinics in the world. , ... Monsey, NY (PRWEB) May 4, 2010 -- The new All Time Medical space ... were physically bound by how many people we were able to hire. We literally couldn,t have ...
... The ... provider while more accurately reflecting its strengths and abilities , ... Baltimore, MD (PRWEB) May 4, 2010 -- ... America, is pleased to announce the completion of its rebranding, establishing itself as Tax ...
Cached Medicine News:Health News:New Study Shows Parents How to Increase Their Kid's Success in Reading 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 3Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 4Health News:Men With HPV at Higher Risk for HIV, Study Finds 2Health News:Investigators examine colorectal cancer screening methods among diverse populations 2Health News:Investigators examine colorectal cancer screening methods among diverse populations 3Health News:Investigators examine colorectal cancer screening methods among diverse populations 4Health News:Investigators examine colorectal cancer screening methods among diverse populations 5Health News:Investigators examine colorectal cancer screening methods among diverse populations 6Health News:Investigators examine colorectal cancer screening methods among diverse populations 7Health News:Investigators examine colorectal cancer screening methods among diverse populations 8Health News:Investigators examine colorectal cancer screening methods among diverse populations 9Health News:Investigators examine colorectal cancer screening methods among diverse populations 10Health News:All Time Medical Has Just Moved To Their New, State-Of-The Art Office Situated In The Heart Of The Business District Of Monsey, N.Y 2Health News:Nationwide Tax Solutions Rebrands Itself as Tax Strategies 2
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: